Oral Antiplatelet and Anticoagulant Agents in the Prevention and Management of Ischemic Stroke.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current pharmaceutical design

• Publication date

  2017-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1381612822666161221145614PMID 28003013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy

  2016cited by this paper
• Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.

  2016cited by this paper
• Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.

  2015cited by this paper
• Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

  2015cited by this paper
• Idarucizumab for Dabigatran Reversal.

  2015cited by this paper
• Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial

  2015cited by this paper
• Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation.

  2015cited by this paper
• Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.

  2015cited by this paper
• Thrombectomy within 8 hours after symptom onset in ischemic stroke.

  2015cited by this paper
• Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.

  2015cited by this paper
• Dual antiplatelet therapy in stroke and ICAS

  2015cited by this paper
• Patient-reported health preferences of anticoagulant-related outcomes

  2015cited by this paper
• Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation

  2014cited by this paper
• Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.

  2014cited by this paper
• Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

  2014cited by this paper
• Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey

  2014cited by this paper
• Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings

  2014cited by this paper
• Edoxaban versus warfarin in patients with atrial fibrillation.

  2013cited by this paper
• Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2)

  2013cited by this paper
• Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.

  2013cited by this paper
• A specific antidote for dabigatran: functional and structural characterization.

  2013cited by this paper
• Association of a higher density of specialist neuroscience providers with fewer deaths from stroke in the United States population.

  2013cited by this paper
• Indications for treatment of recurrent carotid stenosis

  2013cited by this paper
• A Risk Factor-based Predictive Model of Outcomes in Carotid Endarterectomy: The National Surgical Quality Improvement Program 2005–2010

  2013cited by this paper
• Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

  2012cited by this paper
• The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study

  2012cited by this paper
• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

  2012cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Stroke of the posterior cerebral circulation.

  2011cited by this paper
• Apixaban in patients with atrial fibrillation.

  2011cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran

  2011cited by this paper
• Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association.

  2011cited by this paper
• Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study

  2011cited by this paper
• Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

  2011cited by this paper
• Effect of home testing of international normalized ratio on clinical events.

  2010cited by this paper
• Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

  2010cited by this paper
• Predictors of stroke in patients with severe systolic dysfunction in sinus rhythm: role of echocardiography.

  2010cited by this paper
• Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

  2010cited by this paper
• Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

  2010cited by this paper
• Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran

  2010cited by this paper
• Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association

  2009cited by this paper
• Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

  2009cited by this paper
• Antiplatelet therapy for acute ischaemic stroke.

  2008cited by this paper
• Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

  2008cited by this paper
• Nonfasting triglycerides and risk of ischemic stroke in the general population.

  2008cited by this paper
• Risk of Thromboembolism in Heart Failure: An Analysis From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

  2007cited by this paper
• Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials.

  2007cited by this paper
• Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

  2007cited by this paper
• Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.

  2007cited by this paper
• Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

  2007cited by this paper
• Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.

  2006cited by this paper
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

  2006cited by this paper
• High-dose atorvastatin after stroke or transient ischemic attack.

  2006cited by this paper
• Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.

  2005cited by this paper
• Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

  2004cited by this paper
• Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Ph

  2003cited by this paper
• Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis.

  2003cited by this paper
• Body mass index and the risk of stroke in men.

  2002cited by this paper
• Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

  2002cited by this paper
• Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

  2001cited by this paper
• A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.

  2001cited by this paper
• Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

  2001cited by this paper
• Apoptosis in the nervous system

  2000cited by this paper
• Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs.

  2000cited by this paper
• Baseline NIH Stroke Scale score strongly predicts outcome after stroke

  1999cited by this paper
• Pathobiology of ischaemic stroke: an integrated view.

  1999cited by this paper
• Cigarette smoking as a determinant of high-grade carotid artery stenosis in Hispanic, black, and white patients with stroke or transient ischemic attack.

  1998cited by this paper
• CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.

  1997cited by this paper
• A prospective study of body mass index, weight change, and risk of stroke in women.

  1997cited by this paper
• Evolving stroke and the ischemic penumbra

  1996cited by this paper
• Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper
• Low-molecular-weight heparin for the treatment of acute ischemic stroke.

  1995cited by this paper
• Glucose Intolerance and 22‐Year Stroke Incidence: The Honolulu Heart Program

  1994cited by this paper
• Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.

  1994cited by this paper
• Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community

  1994cited by this paper
• The Role of Lifestyle Factors in the Etiology of Stroke: A Population‐Based Case‐Control Study in Perth, Western Australia

  1994cited by this paper
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

  1994cited by this paper
• Smoking cessation and decreased risk of stroke in women.

  1993cited by this paper
• Do stroke units save lives?

  1993cited by this paper
• Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial

  1993cited by this paper
• Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators.

  1993cited by this paper
• Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.

  1992cited by this paper
• Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group.

  1991cited by this paper
• Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.

  1991cited by this paper
• MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group.

  1991cited by this paper
• Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis.

  1991cited by this paper
• The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.

  1990cited by this paper
• Weekly alcohol consumption, cigarette smoking, and the risk of ischemic stroke

  1989cited by this paper
• Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

  1989cited by this paper
• Meta-analysis of relation between cigarette smoking and stroke.

  1989cited by this paper
• Left ventricular thrombi and cerebral embolism.

  1989cited by this paper
• Reduced incidence of left ventricular thrombi with intravenous streptokinase in acute anterior myocardial infarction: prospective evaluation by cross-sectional echocardiography.

  1988cited by this paper
• Cigarette smoking as a risk factor for stroke. The Framingham Study.

  1988cited by this paper
• Impact of thrombolytic therapy on left ventricular mural thrombi in acute myocardial infarction.

  1988cited by this paper
• Ischemic brain edema following occlusion of the middle cerebral artery in the rat. I: The time courses of the brain water, sodium and potassium contents and blood-brain barrier permeability to 125I-albumin.

  1985cited by this paper
• CBF and time thresholds for the formation of ischemic cerebral edema, and effect of reperfusion in baboons.

  1985cited by this paper
• Effect of early systemic thrombolytic therapy on left ventricular mural thrombus formation in acute anterior myocardial infarction.

  1984cited by this paper

• An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives.

  2026cites this paper
• Cyclin D1/CDK coordination with the cellular prion protein upregulated cell proliferation signaling and preserved neurological function in acute IS rats

  2025cites this paper
• Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro

  2024cites this paper
• Integrative Approaches in Acute Ischemic Stroke: From Symptom Recognition to Future Innovations

  2023cites this paper
• The Efficacy of Needle-Warming Moxibustion Combined with Hyperbaric Oxygen Therapy for Ischemic Stroke and Its Effect on Neurological Function

  2022cites this paper
• Association Between Serum C1q Tumor Necrosis Factor-Related Protein 9 and the Clinical Characteristics and Prognosis of Ischemic Stroke

  2021cites this paper
• Prior Antiplatelet Therapy and Stroke Risk in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation

  2021cites this paper
• Early argatroban and antiplatelet combination therapy in acute non-lacunar single subcortical infarct associated with mild intracranial atherosclerosis

  2021cites this paper
• Probing the drug delivery strategies in ischemic stroke therapy

  2020influential citation
• Evaluation of analytic and clinical performance of thrombin-antithrombin complex and D-dimer assay in prognosis of acute ischemic stroke.

  2020cites this paper
• Synthesis and biological evaluation of N-arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2H,4H)-dione as potential antiplatelet agents

  2018cites this paper
• Worldwide epidemiology and trends of adenosine diphosphate (ADP) receptor inhibitors usage

  2017cites this paper
• Editorial: Antiplatelet and Anticoagulation Treatment in Special Populations.

  2017cites this paper